LONDON: Gilead’s pharmacotherapeutic remdesiver is not recommended for patients hospitalized with COVID – 19 even in high risk, a World Health Organization panel said on Friday.
The setback for the advisory drug potion, which has attracted world attention as an effective treatment for COVID-19 in the summer after initial tests showed some promise. But the panel found that ” there is no evidence that Remedicivir has improved significant outcomes for patients such as reduction of mortality, need for mechanical ventilation, clinical improvement time and others,” the guideline said.
Remdicivir is one of the drugs used for covid 19 among two medicines currently authorized to treat COVID-19 patients worldwide, but a large-led trial by WHO called the Solidarity Trial last month showed little or no effect on 28-day mortality or long, Hospital stay for COVID-19 patients.
The latest WHO advice comes after one of the world’s leading organizations representing intensive care physicians said that COVID-19 patients in critical care wards should not use antivirals.
This medicine used to the US. President Trump when he hospitalized with covid 19